Histone deacetylase inhibitors: discovery and development as anticancer agents

Bibliography

• LEHRMANN H, PRITCHARD LL-BELLAN A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. (2002) 86:41–65.
   PubMed Web of Science ®Google Scholar
• LUGER K, MADER AW, RK, SARGENT DF, RICHMOND TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 389:251–260.
   Google Scholar
• MARKS P, RIFKIND RA, RICHON VM et al.: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer (2001) 1:194–202.
   PubMed Web of Science ®Google Scholar
• FISCHLE W, WANG Y ALLIS CD: Binary switches and modification cassettes in histone biology and beyond. Nature (2003) 425:475–479.
   PubMed Web of Science ®Google Scholar
• •Excellent summary of evidence for the `histone code'.
   Google Scholar
• SPOTSWOOD HT, TURNER BM: increasingly complex code.. Clin. Invest. (2002) 110:577–582.
   Google Scholar
• •Another good review of post-translational histone modifications and gene regulation.
   Google Scholar
• ZHANG Y, REINBERG D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. (2001) 15:2343–2360.
   PubMed Web of Science ®Google Scholar
• FELSENFELD G, GROUDINE M: Controlling the double helix. Nature (2003) 421:448–453.
   PubMed Web of Science ®Google Scholar
• KHORASANIZADEH S: The nucleosome: from genomic organization to genomic regulation. Cell (2004) 116:259–272.
   PubMed Web of Science ®Google Scholar
• FISCHLE W, WANG Y ALLIS CD: Histone and chromatin cross-talk. Curr. Opin. Cell Biol. (2003) 15:172–183.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, MILLER T KELLY WK: Histone deacetylase inhibitors. Adv. Cancer Res. (2004) 91:137–168.
   PubMed Web of Science ®Google Scholar
• DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, KUILENBURG AB: Histone deacetylases: characterization of the classical HDAC family. Biochem. j (2002) 370:737–749.
   Web of Science ®Google Scholar
• BLANDER G, GUARENTE L: The Sir2 family of protein deacetylases. Ann. Rev. Biochem (2004) 73:417–435.
   PubMed Web of Science ®Google Scholar
• MET S, HO AD, MAHLKNECHT U: Role of histone deacetylase inhibitors in the treatment of cancer. Int. J. OncoL (2004):1509–1519.
   PubMed Web of Science ®Google Scholar
• BHALLA KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies./ Clin. OncoL (2005) 23:3971–3993.
   PubMed Web of Science ®Google Scholar
• •A good review of HDAC inhibitors and haematological malignancies.
   Google Scholar
• GREGORETTI IV, LEE YM, HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. Mo/. Bid. (2004) 338:17–31.
   PubMed Web of Science ®Google Scholar
• DRUMMOND DC, NOBLE CO, KIRPOTIN DB et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev. PharmacoL lbxicoL (2005) 45:495–528.
   PubMed Web of Science ®Google Scholar
• MARKS P, KELLY W: Histone deacetylase inhibitors: novel targeted anti-cancer agents. In: DNA Methylation, Epigenetic and Metastasis. Esteller M, Springer, Netherlands (2005):269–305.
   Google Scholar
• JOHNSTONE RW, LICHT JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 4:13–18.
   PubMed Web of Science ®Google Scholar
• DI GENNARO E, BRUZZESE F, CARAGLIA M, ABRUZZESE A, BUDILLON A: Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids (2004) 26:435–441.
   PubMed Web of Science ®Google Scholar
• BUTLER LM, ZHOU X, XU W-S et aL: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci USA (2002) 99:11700–11705.
   PubMed Web of Science ®Google Scholar
• •Evidence for a role of the thioredoxin oxidation-redution pathway in the response of cancer cells to HDAC inhibitors.
   Google Scholar
• GUI CY, NGO L, XU WS, RICHON VM, PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA (2004) 101:1241–1246.
   PubMed Web of Science ®Google Scholar
• •Elucidates a mechanism for HDAC inhibitor selective gene activation.
   Google Scholar
• SENGUPTA N, SETO E: Regulation of histone deacetylase activities.. Cell. Biochem. (2004) 93:57–67.
   PubMed Web of Science ®Google Scholar
• WALTREGNY D, DE LEVAL L, GLENISSON Wet al.: Expression of deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am. J. PathoL (2004) 165:553–564.
   Google Scholar
• YANG WM, TSAI SC, WEN YD, G, SETO E: Functional domains of histone deacetylase-3. j Biol. Chem. (2002) 277:9447–9454.
   PubMed Web of Science ®Google Scholar
• ZHOU X, MARKS PA, RIFKIND RA, RICHON VM: Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA (2001) 98:10572–10577.
   PubMed Web of Science ®Google Scholar
• VERDIN E, DEQUIEDT F, HG: Class II histone deacetylases: versatile regulators. Trends Genet. (2003) 19:286–293.
   PubMed Web of Science ®Google Scholar
• •Different biological roles of class I and II HDACs.
   Google Scholar
• GROZINGER CM, SCHREIBER SL: Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. NatL Acad. Sci. USA (2000) 97:7835–7840.
   PubMed Web of Science ®Google Scholar
• LI X, SONG S, LIU Y, KO SH, KAO HY: Phosphorylation of the histone 7 modulates its stability and association with 14-3-3 proteins.. Chem. (2004) 279:34201–34208.
   Google Scholar
• LAGGER G, O'CARROLL D, M et al.: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. (2002) 21:2672–2681.
   Google Scholar
• •Evidence that HDAC1 plays a role in cell proliferation.
   Google Scholar
• KOVACS JJ, MURPHY PJ, GAILLARD S et al.: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. MoL Cell (2005) 18:601–607.
   PubMed Web of Science ®Google Scholar
• ••Evidence that acetylation of non-histonetargets alter activity of proteins involved in cell survival and proliferation.
   Google Scholar
• KAWAGUCHI Y, KOVACS JJ, McLAURIN A et al.: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 115:727–738.
   PubMed Web of Science ®Google Scholar
• MAHLKNECHT U, HOELZER D, BUCALA R, VERDIN E: Cloning and characterization of the murine histone deacetylase (HDAC3). Biochem. Biophys. Res. Commun. (1999) 263:482–490.
   PubMed Web of Science ®Google Scholar
• GROZINGER CM, HASSIG CA, SCHREIBER SL: Three proteins define a of human histone deacetylases related to yeast Hdalp. Proc. NatL Acad. Sci. USA (1999) 96:4868–4873.
   PubMed Web of Science ®Google Scholar
• KAO HY, DOWNES M, P, EVANS RM: Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Den (2000) 14:55–66.
   PubMed Web of Science ®Google Scholar
• DEQUIEDT F, KASLER H, FISCHLE W et al.: HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 18:687–698.
   PubMed Web of Science ®Google Scholar
• KAO HY, LEE CH, KOMAROV A, HAN CC, EVANS RM: Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. j Biol. Chem. (2002) 277:187–193.
   PubMed Web of Science ®Google Scholar
• GAO L, CUETO MA, ASSELBERGS F, ATADJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. (2002) 277:25748–25755.
   PubMed Web of Science ®Google Scholar
• VEGA RB, MATSUDA K, OH J et aL: Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell (2004) 119:555–566.
   PubMed Web of Science ®Google Scholar
• CHANG S, McKINSEY TA, ZHANG CL et al.: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. MoL Cell. Biol. (2004) 24:8467–8476.
   PubMed Web of Science ®Google Scholar
• ZHANG CL, McKINSEY TA, CHANG S et al.: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell (2002) 110:479–488.
   PubMed Web of Science ®Google Scholar
• MEJAT A, RAMOND F,-DUBY R et al.: Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat. Neurosci. (2005) 8:313–321.
   Google Scholar
• TAKAMI Y, KIKUCHI H, NAKAYAMA T: Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line. J. Biol. Chem. (1999) 274:23977–23990.
   PubMed Web of Science ®Google Scholar
• GLASER KB, LI J, STAVER MJ et al.: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. (2003) 310:529–536.
   PubMed Web of Science ®Google Scholar
• ZHU P, MARTIN E, MENGWASSER J et al.: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 5:455–463.
   PubMed Web of Science ®Google Scholar
• TAKAMI Y, NAKAYAMA T: N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J. Biol. Chem. (2000) 275:16191–16201.
   PubMed Web of Science ®Google Scholar
• TOU L, LIU Q, SHIVDASANI RA: Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases.. Cell. Biol. (2004) 24:3132–3139.
   Web of Science ®Google Scholar
• LIU F, DOWLING M, YANG XJ, KAO GD: Caspase-mediated specific cleavage of human histone deacetylase 4. J. Biol. Chem. (2004) 279:34537–34546.
   PubMed Web of Science ®Google Scholar
• HUANG Y, TAN M, GOSINK M, WANG KK, SUN Y: Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res. (2002) 62:2913–2922.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, LI N, CARON C et ell.: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. (2003) 22:1168–1179.
   Google Scholar
• ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21–38.
   PubMed Web of Science ®Google Scholar
• CHOI JH, KWON HJ, YOON BI et aL: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. (2001) 92:1300–1304.
   PubMedGoogle Scholar
• HALKIDOU K, GAUGHAN L, COOKS et al.: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 59:177–189.
   PubMed Web of Science ®Google Scholar
• LINDEMANN RK, GABRIELLI B, JOHNSTONE RW: Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle (2004) 3:779–788.
   PubMed Web of Science ®Google Scholar
• SHEBZUKHOV YV, KOROLEVA EP, KHLGATIAN SV et al.: Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int. J. Cancer (2005) 117(5):800–806.
   PubMed Web of Science ®Google Scholar
• OSADA H, TATEMATSU Y, SAITO H et al.: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.. J. Cancer (2004) 112:26–32.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, WELTS, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. (2002) 62:4041–4047.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, YAMASHITA H, T et al.: HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. (2004) 10:6962–6968.
   PubMed Web of Science ®Google Scholar
• HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPARS is an APC-regulated target of nonsteroicial anti-inflammatory drugs. Cell (1999) 99:335–345.
   PubMed Web of Science ®Google Scholar
• YOSHIDA N, OMOTO Y, INOUE A et al.: Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. (2004) 95:496–502.
   PubMedGoogle Scholar
• MILLER TA, WITTER DJ, BELVEDERE S: Histone deacetylase inhibitors. J. Med. Chem. (2003) 46:5097–5116.
   PubMed Web of Science ®Google Scholar
• •Good review of the chemistry of HDAC inhibitors.
   Google Scholar
• RICHON VM, EMILIANI S, VERDIN E et al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. NatL Acad. Sci. USA (1998) 95:3003–3007.
   PubMed Web of Science ®Google Scholar
• JOSE B, ONIKI Y, KATO T et aL: Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg. Med. Chem. Lett. (2004) 14:5343–5346.
   PubMed Web of Science ®Google Scholar
• CURTIN M, GLASER K: Histone deacetylase inhibitors: the abbott experience. Curr. Med. Chem. (2003) 10:2373–5392.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, MATSUYAMA A, KOMATSU Y, NISHINO N: From discovery to the coming generation of histone deacetylase inhibitors.. Med. Chem. (2003) 10:2351–2358.
   Web of Science ®Google Scholar
• •Describes development of structurally new HDAC inhibitors.
   Google Scholar
• GAREA-VILLAR A. ESTELLER M: histone deacetylase inhibitors: understatnding a new wave of anticancer agents. Int. J. Cancer (2004) 112:171–178.
   PubMed Web of Science ®Google Scholar
• PARK JH, JUNG Y, KIM TY et al.: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. (2004) 10:5271–5281.
   PubMed Web of Science ®Google Scholar
• HAGGARTY SJ, KOELLER KM, WONG JC, GROZINGER CM, SCHREIBER SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA (2003) 100:4389–4394.
   PubMed Web of Science ®Google Scholar
• ••First discovery of a HDAC-specificinhibitor.
   Google Scholar
• FINNIN MS, DONIGIAN JR, A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188–193.
   PubMed Web of Science ®Google Scholar
• ••First description of the structure of HDACcatalytic site, and the possible mechanism of TSA and SAHA inhibition of these enzymes.
   Google Scholar
• SOMOZA JR, SKENE RJ, KATZ BA et al: Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 12:1325–1334.
   PubMed Web of Science ®Google Scholar
• •First description of the structure of the catalytic site of a mammalian HDAC.
   Google Scholar
• GRAY SG, QIAN CN, FURGE K, GUO X, TEH BT: Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol (2004) 24:773–795.
   PubMed Web of Science ®Google Scholar
• •Evidence for the selective effects of HDAC inhibitors on gene expression.
   Google Scholar
• PEART MJ, SMYTH GK, VAN LAAR RK et al.: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2005) 102:3697–3702.
   Google Scholar
• MITSIADES CS, MITSIADES NS, McMULLAN CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA (2004) 101:540–545.
   PubMed Web of Science ®Google Scholar
• RASCLE A, JOHNSTON JA, AMATI B: Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol. (2003) 23:4162–4173.
   PubMed Web of Science ®Google Scholar
• VAN LINT C, EMILIANI S, VERDIN E: The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Exp. (1996) 5:245–254.
   PubMed Web of Science ®Google Scholar
• •First study to show that the HDAC inhibitor class is selective in altering the expression of genes.
   Google Scholar
• CHAMBERS AE, BANERJEE S, CHAPLIN T et al.: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer (2003) 39:1165–1175.
   PubMed Web of Science ®Google Scholar
• RICHON VM, SANDHOFF TW, RIFKIND RA, MARKS PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA (2000) 97:10014–10019.
   PubMed Web of Science ®Google Scholar
• WARRENER R, BEAMISH H, BURGESS A et al.: Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. (2003) 17:1550–1552.
   PubMed Web of Science ®Google Scholar
• ZHU P, HUBER E, KIEFER F, M: Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle (2004) 3:1240–1242.
   PubMed Web of Science ®Google Scholar
• BURGESS A, RUEFLI A, BEAMISH H et al.: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene (2004) 23:6693–6701.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that HDAC inhibitors kill both proliferating and non-proliferating cancer cells.
   Google Scholar
• UNGERSTEDT JS, SOWA Y, XU WS et al: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA (2005) 102:673–678.
   PubMed Web of Science ®Google Scholar
• ••Describes a possible mechanism toexplain the sensitivity of normal cells and resistance of transformed cells to HDAC inhibitors.
   Google Scholar
• MARKS PA, JIANG X: Histone deacetylaseinhibitors in programmed cell death and cancer therapy. Cell Cycle (2005) 4:e8-el 1.
   Google Scholar
• XU W-S, PEREZ G, NGO L, GUI C-Y, MARKS PA: Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. (2005) 65(17):7832–7839.
   PubMed Web of Science ®Google Scholar
• SHAO Y, GAO Z, MARKS PA, JIANG X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2004) 101:18030–18035.
   PubMed Web of Science ®Google Scholar
• ROSATO RR, ALMENARA JA, DAI Y, GRANT S: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. (2003) 2:1273–1284.
   PubMed Web of Science ®Google Scholar
• POWIS G, MUSTACICH D, COON A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic.. Med. (2000) 29:312–322.
   PubMed Web of Science ®Google Scholar
• HOLMGREN A: Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid. Redox Signal (2000) 2:811–820.
   PubMed Web of Science ®Google Scholar
• RUNDLOF AK ARNER ES: Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal (2004) 6:41–52.
   PubMed Web of Science ®Google Scholar
• ARNER ES, HOLMGREN A: functions of thioredoxin and reductase. Eur. J. Biochem. (2000) 267:6102–6109.
   PubMedGoogle Scholar
• •Excellent review of the role of thioredoxin oxidation-reduction system in cell proliferation and cell death.
   Google Scholar
• PIEKARZ R, BATES S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.. Pharm. Des. (2004) 10:2289–2298.
   Google Scholar
• GUO F, SIGUA C, TAO J et al: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. (2004) 64:2580–2589.
   PubMed Web of Science ®Google Scholar
• COFFEY DC, KUTKO MC, GLICK RD et al.: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. (2001) 61:3591–3594.
   PubMed Web of Science ®Google Scholar
• YOSHIDA C, MELO JV: Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. j HematoL (2004) 79:420–433.
   PubMed Web of Science ®Google Scholar
• PEI XY, DAI Y, GRANT S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.. Cancer Res. (2004) 10:3839–3852.
   Web of Science ®Google Scholar
• GEORGE P, BALI P, ANNAVARAPU S et al.: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood (2005) 105: 1768-1776.
   Google Scholar
• FUINO L, BALI P, WITTMANN S et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Cancer Ther. (2003) 2:971–984.
   Google Scholar
• KELLY WK, O'CONNOR OA, KRUG L et al.: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J. Clin. Oncol. (2005) 23:3923-3931. report of completed Phase I clinical in cancer patients with an orally administered HDAC inhibitor, SAHA.
   Google Scholar
• MIE LEE Y, KIM SH, KIM HS et cll.: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-la activity. Biochem. Biophys. Res. Commun. (2003) 300:241–246.
   Google Scholar
• BLANCHARD F, KINZIE E, WANG Y et al.: FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by the expression of receptor proteins. Oncogene (2002) 21:6264–6277.
   PubMed Web of Science ®Google Scholar
• PIEKARZ RL, ROBEY RW, ZHAN Z et al.: T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood (2004) 103:4636–4643.
   PubMed Web of Science ®Google Scholar
• KELLY W, MARKS P: Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clinical Practice Oncology (2005) 2:150–157.
   PubMedGoogle Scholar
• DUVIC M, RAKHSHANDRA T, CHIAO J, CHIAO N: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood (2003) 102(11):625 (Abstract).
   Google Scholar
• KUENDGEN A, STRUPP C, AIVADO M et al.: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood (2004) 104:1266–1269.
   PubMed Web of Science ®Google Scholar
• NERVI C, COCO FL, MINUCCI S et aL: Valproic acid plus retinoic acid induce myeloid differentiation in chemotherapy-resistant acute myeloid leukemia patients. ASH Annual Meeting Abstracts (2004) 104:1805.
   Google Scholar
• DOKMANOVIC M, MARKS PA: Prospects: histone deacetylase inhibitors. J. Cell. Biochem. (2005) 96:293–304.
   PubMed Web of Science ®Google Scholar